Cantor Fitzgerald analyst Prakhar Agrawal reiterated a Buy rating on Aclaris Therapeutics today. The company’s shares opened today at $1.85.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Agrawal covers the Healthcare sector, focusing on stocks such as aTyr Pharma, Structure Therapeutics, Inc. Sponsored ADR, and Madrigal Pharmaceuticals. According to TipRanks, Agrawal has an average return of 1.7% and a 36.27% success rate on recommended stocks.
Currently, the analyst consensus on Aclaris Therapeutics is a Moderate Buy with an average price target of $7.92, which is a 328.11% upside from current levels. In a report released today, Piper Sandler also maintained a Buy rating on the stock with a $6.00 price target.
Based on Aclaris Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $1.78 million and a GAAP net loss of $15.43 million. In comparison, last year the company earned a revenue of $2.77 million and had a GAAP net loss of $10.99 million
/AI%20(artificial%20intelligence)/Artificial%20intelligence%20and%20machine%20learning%20concept%20-%20by%20amgun%20via%20iStock.jpg)
/Broadcom%20Inc%20logo%20on%20building-by%20Poetra_%20RH%20via%20Shutterstock.jpg)
/Oracle%20Corp_%20logo%20on%20phone-by%20WonderPix%20via%20Shutterstock.jpg)
